Form 4, and a Schedule 13D amendment were filed at the SEC EDGAR window -- the former of which indicates that in a private transaction (apparently one buyer, with two separate tranches), on last Thursday and Friday -- Martin Shkreli disposed of 1,222,929 shares -- i.e., all his remaining shares of KaloBios -- at $3.10.
That $3.10 figure represents about a 10 per cent discount to those days' NASDAQ pink sheet quoted trading prices.
So, now we wait to see if KaloBios was the buyer (at the agreed discount for the call) -- or if it was someone else. [UPDATE: I suppose it could be that all parties agreed that Sable Fiduciary Limited, on behalf of Cortleigh Limited, could step in and acquire. If you've been reading the sattelite site, you'll likely recall that last month, a BVI/UK entity or set of entities acquired more than a million KaloBios shares -- maybe seeing an easy way to add to the position -- on the cheap. On a moment's reflection, I must admit to that possibility.]
SECOND UPDATE -- Per PathoPhilia, John Carroll, at EndPoints -- reports that Dr. Durrant confirms it was a third party buyer -- which would mean that KaloBios agreed to the investor -- and the terms. So now I am guessing it is the BVI and British investors mentioned above (graphic at right). They will then amend that SEC Schedule 13 at quarter's end.